Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Olaparib Tablets in Healthy Subjects
NCT06360445Phase 1Completed
- Sponsor
- CSPC Ouyi Pharmaceutical
- Start
- May 2022
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of olaparib in ovarian cancer, breast cancer, pancreatic cancer (PC) and 1 more (6 arms), sponsored by CSPC Ouyi Pharmaceutical. Primary endpoints: Maximum observed plasma concentration, Area under the plasma concentration time curve from time zero extrapolated to infinite time and 1 more. Started May 2022; status: completed.
02
Drugs
olaparib
03
Conditions
ovarian cancerbreast cancerpancreatic cancer (PC)prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06360445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06360445.